Compare TYRA & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | TROX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2021 | 2012 |
| Metric | TYRA | TROX |
|---|---|---|
| Price | $20.07 | $3.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 8 |
| Target Price | ★ $47.45 | $5.81 |
| AVG Volume (30 Days) | 957.1K | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 5.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,898,000,000.00 |
| Revenue This Year | N/A | $13.36 |
| Revenue Next Year | N/A | $4.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.35 | $2.86 |
| 52 Week High | $40.65 | $10.59 |
| Indicator | TYRA | TROX |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 26.04 |
| Support Level | $18.66 | N/A |
| Resistance Level | $27.00 | $4.53 |
| Average True Range (ATR) | 1.12 | 0.18 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 7.94 | 3.41 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.